Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours Β· Estimated delivery Oct 23 - Oct 28
New England Journal of Medicine (2025) This phase 3b open-label trial provided the first direct head-to-head comparison of tirzepatide and semaglutide for obesity, randomizing 751 adults without diabetes to maximum tolerated doses of tirzepatide (10 or 15mg weekly) or semaglutide (1.7 or 2.4mg weekly) for 72 weeks
It keeps injection volumes low even at the 8mg dose (80 units) and only requires a split at 12mg
The relationship is complex and not definitively established
Pu X, Lin X, Duan X, Wang J, Shang J, Yun H, et al
1265.54 Semaglutide Impurity 68 C 43 H 79 N 3 O 13 M.W
US$ 22.63
US$ 22.33
US$ 20.37
